Berberine associated to Dapagliflozin exerts synergistic cardioprotective effects in cardiac cells exposed to the HER2-bloking agent Trastuzumab through pAMPK activation and reduction in Interleukin-6 levels
Anno:
2023
Background: Trastuzumab has improved the prognosis in patients with HER2-positive breast cancer, but it can induce left ventricular dysfunction with reduced ejection fraction or HF during treatment. Dapagliflozin is a SGLT2i with cardio-renal benefits. In the DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial, the sodium-glucose cotransporter…